ANNX VS ABOS Stock Comparison

PerformanceSentimentTechnicalsEarningsProfitVolatility
PerformanceSentimentTechnicalsEarningsProfitVolatility

Performance

ANNX
10/100

ANNX returned -58.14% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

ABOS
10/100

ABOS returned -66.56% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Sentiment

ANNX
72/100

ANNX had a bullish sentiment score of 71.85% across Twitter and StockTwits over the last 12 months. It had an average of 2.00 posts, 0.00 comments, and 0.07 likes per day.

ABOS

"Sentiment" not found for ABOS

Technicals

ANNX
64/100

ANNX receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

ABOS
32/100

ABOS receives a 32 of 100 based on 14 indicators. 4 are bullish, 9 are bearish.

Earnings

ANNX
10/100

ANNX has missed earnings 7 times in the last 20 quarters.

ABOS
30/100

ABOS has missed earnings 3 times in the last 20 quarters.

Profit

ANNX
10/100

Out of the last 19 quarters, ANNX has had 0 profitable quarters and has increased their profits year over year on 1 of them.

ABOS
10/100

Out of the last 15 quarters, ABOS has had 0 profitable quarters and has increased their profits year over year on 1 of them.

Volatility

ANNX
49/100

ANNX has had a lower than average amount of volatility over the last 12 months giving it a score of 49 of 100.

ABOS
37/100

ABOS has had a lower than average amount of volatility over the last 12 months giving it a score of 37 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Annexon, Inc. Common Stock Summary

Nasdaq / ANNX
Healthcare
Biotechnology
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Acumen Pharmaceuticals, Inc. Common Stock Summary

Nasdaq / ABOS
Healthcare
Biotechnology
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.